Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

Effects of sodium‐glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials

(2019) Jingli Lu et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials

(2019) Giovanni Musso et al.   BMJ-British Medical Journal

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial

(2019) Mark E. Cooper et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study

(2018) John B. Buse et al.   DIABETES CARE

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

(2018) Chantal Mathieu et al.   DIABETES CARE

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

(2018) Julio Rosenstock et al.   DIABETES CARE

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

(2018) Thomas A Zelniker et al.   LANCET

Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus

(2017) John Mondick et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

(2017) Satish K. Garg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

(2017) Paresh Dandona et al.   Lancet Diabetes & Endocrinology

The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management

(2016) Ebenezer A. Nyenwe et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes

(2016) Kyle T. Baron et al.   Diabetes Therapy

Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes

(2016) Kyle T. Baron et al.   Diabetes Therapy

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)

(2015) T. R. Pieber et al.   DIABETES OBESITY & METABOLISM